ASH 2020

red blood cells
Biotech

UniQure/CSL hem B gene therapy curbs bleeding in phase 3

CSL and uniQure's hemophilia B gene therapy curbed bleeding episodes by 91% and nearly eliminated the need for infusions of clotting factors.
Amirah Al Idrus Dec 8, 2020 10:10am
Novartis headquarters

Novartis' asciminib tops Pfizer's Bosulif in head-to-head trial

Dec 8, 2020 10:00am
Mouse

CRISPR-edited CAR-Ts show enhanced activity in leukemia models

Dec 7, 2020 8:45am
Allogene Therapeutics Co-Founders Arie Belldegrun and David Chang

Allogene CAR-T posts 60% response rate in competitive BCMA field

Dec 7, 2020 8:03am
Regeneron

Regeneron's bispecific banishes 2 kinds of lymphoma

Dec 6, 2020 3:00pm
JJ

ASH: J&J’s subcut BCMA bispecific hits 73% response rate

Dec 5, 2020 3:00pm